Compare Bank of New York Mellon Corp (BNY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Recursion Pharmaceuticals Inc — how do they compare? Bank of New York Mellon Corp trades at $161 (market cap $108.17B), while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B). The key difference: Bank of New York Mellon Corp is far larger — about 60.8× Recursion Pharmaceuticals Inc's market cap, and Bank of New York Mellon Corp pays a 1.39% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BNY | RXRX | |
|---|---|---|
Market Cap | $108.17B | $1.78B |
Sector | Financials | Health |
52-Week High | $162.35 | $6.79 |
52-Week Low | $101.00 | $2.84 |
Dividend Yield | 1.39% | — |
Enterprise Value | — | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY trades at $157.65, down 0.75% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.46 exceeding expectations. Revenue and net income have shown steady growth, with 2025 revenue at $19.76 billion and net income at $5.55 billion. Recent news highlights BNY's expansion into digital transfer agency capabilities and a strategic collaboration with Galaxy Digital to advance digital asset infrastructure, signaling innovation in fund servicing.
The outlook for BNY is positive, supported by strong earnings performance, a consensus price target of $170.36, and a bullish analyst rating upgrade to Strong Buy by Zacks. Investment opportunities include continued revenue growth and margin expansion. Risks involve high investing cash outflows, competitive pressures in custody banking, and sensitivity to interest rate changes. The stock offers a dividend yield with recent increases, appealing to income-focused investors amid solid fundamentals.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
